Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 55 citing articles:

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke, Piotr Rutkowski, Paola Queirolo, et al.
The Lancet (2022) Vol. 399, Iss. 10336, pp. 1718-1729
Closed Access | Times Cited: 401
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 5, pp. 643-654
Closed Access | Times Cited: 315
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview
Silvie H. M. Janssen, Winette T.A. van der Graaf, Daniël J. van der Meer, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4847-4847
Open Access | Times Cited: 114
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
NEJM Evidence (2022) Vol. 1, Iss. 11
Closed Access | Times Cited: 105
The Treatment of Advanced Melanoma: Therapeutic Update
Alessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6388-6388
Open Access | Times Cited: 83
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 20
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Minke W. Lucas, Judith M. Versluis, Elisa A. Rozeman, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 408-422
Closed Access | Times Cited: 28
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
Jingjing Su, Yiting Fu, Zitong Cui, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 13
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113601-113601
Closed Access | Times Cited: 6
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kiciński, Mario Mandalà, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1202-1212
Closed Access | Times Cited: 5
Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
Ioannis Anestopoulos, Sotiris Kyriakou, Venetia Tragkola, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108301-108301
Closed Access | Times Cited: 21
Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy
Sidsel Pedersen, Rikke Boedker Holmstroem, Annika von Heymann, et al.
Acta Oncologica (2023) Vol. 62, Iss. 1, pp. 62-69
Open Access | Times Cited: 13
Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review
Julia Lai‐Kwon, Andrisha–Jade Inderjeeth, Karolina Lisy, et al.
European Journal of Cancer (2023) Vol. 184, pp. 83-105
Closed Access | Times Cited: 12
Adjuvant therapy for stage II melanoma: the need for further studies
Rebecca Lee, Mario Mandalà, Georgina V. Long, et al.
European Journal of Cancer (2023) Vol. 189, pp. 112914-112914
Open Access | Times Cited: 12
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander M.M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
European Journal of Cancer (2021) Vol. 158, pp. 156-168
Open Access | Times Cited: 25
Individualized Neoantigen-Directed Melanoma Therapy
Karam Khaddour, Elizabeth I. Buchbinder
American Journal of Clinical Dermatology (2025)
Closed Access
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial
John M. Kirkwood, Peter Mohr, Christoph Höeller, et al.
European Journal of Cancer (2025), pp. 115371-115371
Open Access
Monoclonal antibodies as adjuvant therapies for resected melanoma
Islam Eljilany, Julita García, Basem T. Jamal, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-14
Closed Access
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 15
Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment
Piotr Rutkowski, Mario Mandalà
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 3, pp. 107969-107969
Closed Access | Times Cited: 3
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
Jason J. Luke, Georgina V Long, Caroline Robert, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114146-114146
Open Access | Times Cited: 3
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, et al.
European Journal of Cancer (2022) Vol. 176, pp. 207-217
Open Access | Times Cited: 14
Systemic adjuvant therapy for high-risk cutaneous melanoma
Iyad Kobeissi, Ahmad A. Tarhini
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 14
Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module
Mees Egeler, M van Leeuwen, Julia Lai‐Kwon, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114176-114176
Closed Access | Times Cited: 2
Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Aasha I. Hoogland, Andrew S. Brohl, Brent J. Small, et al.
Cancer Medicine (2024) Vol. 13, Iss. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top